view more

Company Formation, Business Development, Fundraising and Consulting with a Global Perspective

Biotech  -  Pharma  -  Medtech
What we can do for you
 

Consulting Services

We provide experience-based consulting services for Biotech, Pharma and Medtech clients globally. Technical consulting, project management, strategy and management consulting, market and opportunity analyses are some of our core areas of expertise.

go

Company Creation

Ventac Partners has a global network of Life Science investors in Europe, US and Asia as well as expertise in founding and growing companies on behalf of clients. Unlike other consulting agencies, we also found, actively manage, grow and help exit innovative Portfolio Companies co-owned with partners & investors.

go

Corporate Development

We offer extensive buy and sell-side transaction experience with a truly international reach in virtually all Life Science sectors. Our specialties include in- and out-licensing, mergers & acquisitions, business development and marketing collaborations in all continents.

go
  • 12.2015

    Avexxin, a VP portfolio company focused on development of anti-inflammatory drugs, raises additional USD 2.5M from existing shareholders. Avexxin achieved Proof-of-Concept in man in a second phase I/IIa trial mid-2015.

  • 11.2015

    RhoVac, a VP portfolio company developing a therapeutic cancer vaccine to eliminate metastases, raises an undisclosed amount in a pre-IPO round. The company is headed for public listing in Sweden early 2016.

  • 10.2015

    Miacom Diagnostics, a VP portfolio company focused on the development and production of medical tests for the detection of acute infectious diseases, announced that the U.S. Patent and Trademark Office has issued a new patent on innovative DNA probes that can be used to provide pathogen detection by means of multiplex FISH assays. A copy of Miacom's press release is available at the following link.

  • 12.2015

    The journal Kemivärlden Biotech features an article on Ventac portfolio company, Idogen, highlighting the company’s work on the development of tolerogenic vaccines. To read the article (in Swedish), please follow this link.

  • 12.2015

    Several partners will attend the Biotech Showcase vis-à-vis JP Morgan conference in San Francisco in January 2016.

  • 11.2015

    CEO of Idogen, Lars Hedbys, presents the company at Sedermeradagen in Stockholm. The presentation can be viewed at this link (Swedish).

  • 11.2015

    Avexxin, a VP portfolio company, will be participating at BIO-Europe 2015, November 2-4 Munich, Germany.

  • 11.2015

    Several Ventac Partners will be participating at BIO-Europe 2015, November 2-4 Munich, Germany.

Subscribe to our Newsletter

Thank you!